Skip to main content
    S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.85
    -0.28 (-2.76%)

    Market Cap: $728.71M

    Last updated: Nov 17, 2026 at 4:18 PM ET

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a market cap of $728.71M and an enterprise value of $617.75M. Its share count is up 92.02% from a year earlier. It holds $110.96M more cash than debt, 15.23% of its market cap.

    Total Valuation

    Enterprise value is 15.23% below the market cap, as cash exceeds debt.

    Market Cap$728.71M
    Enterprise Value$617.75M
    Latest price (Nov 17, 2026)$9.85

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 17.37% in the quarter ended Sep 30, 2026 and grew 39.26% a year over 2 years.

    Shares Outstanding62.34M
    Shares Change (YoY)+92.02%
    Shares Change (QoQ)+17.37%
    Share Count Growth (2Y CAGR)+39.26%

    Price Statistics

    The stock is up 27.10% over 52 weeks and trades at its 50-day average.

    Beta (1Y)1.88
    52-Week Change+27.10%
    1-Month Change+11.17%
    3-Month Change-6.90%
    6-Month Change+50.61%
    Total Return (1Y)+27.10%
    Total Return (3Y CAGR)+49.28%
    Return vs SPY (1Y)+14.40%
    Max Drawdown (1Y)-42.04%
    Max Drawdown (3Y)-89.69%
    Sharpe Ratio (1Y)0.29
    Correlation with SPY (1Y)0.33
    50-Day Average$9.85
    200-Day Average$7.75
    52-Week Range$4.50 to $11.45
    RSI (14 Days)48.6
    Average Volume (20 Days)1.04M

    Price chart

    Financial Position

    Current assets cover 6.34x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.34x
    Quick Ratio6.34x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -22.02% and return on assets is -18.90% over the last 12 months.

    Return on Equity (ROE)-22.02%
    Return on Assets (ROA)-18.90%
    ROA (5Y Average)-46.96%

    Scores

    SGMT has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$59.86M
    Pretax Income-$53.32M
    Net Income-$53.32M
    Reported EPS (TTM)-$1.19

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 85.85% of the $282.09M in total assets.

    Cash and Equivalents$110.96M
    Total Debt$0
    Net Cash$110.96M
    Net Cash Per Share$1.78
    Working Capital$202.74M
    Shareholder Equity$242.18M
    Book Value Per Share$3.88
    Total Assets$282.09M
    Total Liabilities$39.91M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$43.66M
    FCF Per Share-$0.62
    Depreciation and Amortization$754.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-17.05%
    Tangible Book Per Share Growth (2Y CAGR)-17.05%

    Revenue and profit by year

    Dividends and Yields

    SGMT does not pay a dividend.

    Buyback Yield-28.50%
    Shareholder Yield-28.50%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SGMT

    What is SGMT's market cap?

    Sagimet Biosciences Inc. Series A Common Stock has a market cap of $728.71M. Its enterprise value, which adds debt and subtracts cash, is $617.75M.

    How many shares of SGMT are outstanding?

    Sagimet Biosciences Inc. Series A Common Stock has 62.34M shares outstanding. The count is up 92.02% from a year earlier.

    Does SGMT pay a dividend?

    No. Sagimet Biosciences Inc. Series A Common Stock does not pay a dividend.

    How much debt does SGMT have?

    Sagimet Biosciences Inc. Series A Common Stock has $0 of total debt and $110.96M of cash and equivalents, a net cash position of $110.96M.